相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Established and Experimental Systemic Treatment Options for Advanced Liposarcoma
Patrick Schoffski
ONCOLOGY RESEARCH AND TREATMENT (2022)
A Proposed Staging System for Improved Prognostication of MDM2-amplified Liposarcoma
Jonathan J. Tucci et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Gronchi et al.
ANNALS OF ONCOLOGY (2021)
A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
M. Gounder et al.
ANNALS OF ONCOLOGY (2021)
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
Patricia LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives
Jun Nishio et al.
JOURNAL OF CLINICAL MEDICINE (2021)
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia et al.
PATHOLOGICA (2021)
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
J. Cornillie et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
Nanthip Prathumsap et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine
Adriana C. Gamboa et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study
M. Vos et al.
EJSO (2019)
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center
Ciska Langmans et al.
ONCOLOGY RESEARCH AND TREATMENT (2019)
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
Marion Savina et al.
BMC MEDICINE (2017)
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Kate Lynn J. Bill et al.
CLINICAL CANCER RESEARCH (2016)
Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies
Khin Thway et al.
ADVANCES IN ANATOMIC PATHOLOGY (2016)
Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review
Mohamad Farid et al.
ONCOLOGIST (2016)
Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma
Alessandro Gronchi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients
S. H. Tirumani et al.
EJSO (2015)
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas
Mrinal Gounder et al.
EUROPEAN JOURNAL OF CANCER (2015)
Optimizing Dosing of Oncology Drugs
L. Minasian et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project
C. A. Stiller et al.
EUROPEAN JOURNAL OF CANCER (2013)
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival
A. Italiano et al.
ANNALS OF ONCOLOGY (2012)
Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis
Markus P. Ghadimi et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
Francoise Ducimetiere et al.
PLOS ONE (2011)
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
Martin Jenkins et al.
PHARMACEUTICAL STATISTICS (2011)
Doxorubicin: The Good, the Bad and the Ugly Effect
Cristina Carvalho et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Adaptive designs for confirmatory clinical trials
Frank Bretz et al.
STATISTICS IN MEDICINE (2009)
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
Samuel Singer et al.
CANCER RESEARCH (2007)
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk
Kimberly Moore Dalal et al.
ANNALS OF SURGERY (2006)
Differential sensitivity of liposarcoma subtypes to chemotherapy
RL Jones et al.
EUROPEAN JOURNAL OF CANCER (2005)
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes -: A comparative analysis of 559 soft tissue neoplasms with genetic data
MBN Binh et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma
S Singer et al.
ANNALS OF SURGERY (2003)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
分享论文
